|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Blumenthal-Barby JS, Lee D and Volk RJ:
Toward ethically responsible choice architecture in prostate cancer
treatment decision-making. CA Cancer J Clin. 65:257–260. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chan JM, Stampfer MJ and Giovannucci EL:
What causes prostate cancer? A brief summary of the epidemiology.
Semin Cancer Biol. 8:263–273. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Levesque C and Nelson PS: Cellular
constituents of the prostate stroma: Key contributors to prostate
cancer progression and therapy resistance. Cold Spring Harb
Perspect Med. 8(pii): a0305102018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Garisto JD and Klotz L: Active
surveillance for prostate cancer: How to do it right. Oncology
(Williston Park). 31:333–340, 345. 2017.PubMed/NCBI
|
|
6
|
Shepard DR and Raghavan D: Innovations in
the systemic therapy of prostate cancer. Nat Rev Clin Oncol.
7:13–21. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ameres SL and Zamore PD: Diversifying
microRNA sequence and function. Nat Rev Mol Cell Biol. 14:475–488.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Berindan-Neagoe I, Monroig PC, Pasculli B
and Calin GA: MicroRNAome genome: A treasure for cancer diagnosis
and therapy. CA Cancer J Clin. 64:311–336. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Carthew RW and Sontheimer EJ: Origins and
mechanisms of miRNAs and siRNAs. Cell. 136:642–655. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bartels CL and Tsongalis GJ: MicroRNAs:
Novel biomarkers for human cancer. Clin Chem. 55:623–631. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cai C, Chen QB, Han ZD, Zhang YQ, He HC,
Chen JH, Chen YR, Yang SB, Wu YD, Zeng YR, et al: miR-195 inhibits
tumor progression by targeting RPS6KB1 in human prostate cancer.
Clin Cancer Res. 21:4922–4934. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Josson S, Gururajan M, Hu P, Shao C, Chu
GY, Zhau HE, Liu C, Lao K, Lu CL, Lu YT, et al: miR-409-3p/-5p
promotes tumorigenesis, epithelial-to-mesenchymal transition, and
bone metastasis of human prostate cancer. Clin Cancer Res.
20:4636–4646. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu C, Kelnar K, Liu B, Chen X,
Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, et
al: The microRNA miR-34a inhibits prostate cancer stem cells and
metastasis by directly repressing CD44. Nat Med. 17:211–215. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rajendiran S, Parwani AV, Hare RJ,
Dasgupta S, Roby RK and Vishwanatha JK: MicroRNA-940 suppresses
prostate cancer migration and invasion by regulating MIEN1. Mol
Cancer. 13:2502014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Luo H, Guo W, Wang F, You Y, Wang J, Chen
X, Wang J, Wang Y, Du Y, Chen X, et al: miR-1291 targets mucin 1
inhibiting cell proliferation and invasion to promote cell
apoptosis in esophageal squamous cell carcinoma. Oncol Rep.
34:2665–2673. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tu MJ, Pan YZ, Qiu JX, Kim EJ and Yu AM:
MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic
cancer cell proliferation and tumorigenesis. Oncotarget.
7:45547–45561. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yamasaki T, Seki N, Yoshino H, Itesako T,
Yamada Y, Tatarano S, Hidaka H, Yonezawa T, Nakagawa M and Enokida
H: Tumor-suppressive microRNA-1291 directly regulates glucose
transporter 1 in renal cell carcinoma. Cancer Sci. 104:1411–1419.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Soufi-Zomorrod M, Hajifathali A, Kouhkan
F, Mehdizadeh M, Rad SM and Soleimani M: MicroRNAs modulating
angiogenesis: miR-129-1 and miR-133 act as angio-miR in HUVECs.
Tumour Biol. 37:9527–9534. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Turkbey B, Brown AM, Sankineni S, Wood BJ,
Pinto PA and Choyke PL: Multiparametric prostate magnetic resonance
imaging in the evaluation of prostate cancer. CA Cancer J Clin.
66:326–336. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fendler A, Stephan C, Yousef GM and Jung
K: MicroRNAs as regulators of signal transduction in urological
tumors. Clin Chem. 57:954–968. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gade P, Singh AK, Roy SK, Reddy SP and
Kalvakolanu DV: Down-regulation of the transcriptional mediator
subunit Med1 contributes to the loss of expression of
metastasis-associated dapk1 in human cancers and cancer cells. Int
J Cancer. 125:1566–1574. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang Y, Leonard M, Zhang Y, Zhao D,
Mahmoud C, Khan S, Wang J, Lower EE and Zhang X: HER2-driven breast
tumorigenesis relies upon interactions of the estrogen receptor
with coactivator MED1. Cancer Res. 78:422–435. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hulf T, Sibbritt T, Wiklund ED, Patterson
K, Song JZ, Stirzaker C, Qu W, Nair S, Horvath LG, Armstrong NJ, et
al: Epigenetic-induced repression of microRNA-205 is associated
with MED1 activation and a poorer prognosis in localized prostate
cancer. Oncogene. 32:2891–2899. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jin F, Irshad S, Yu W, Belakavadi M,
Chekmareva M, Ittmann MM, Abate-Shen C and Fondell JD: ERK and AKT
signaling drive MED1 overexpression in prostate cancer in
association with elevated proliferation and tumorigenicity. Mol
Cancer Res. 11:736–747. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen Z, Zhang C, Wu D, Chen H, Rorick A,
Zhang X and Wang Q: Phospho-MED1-enhanced UBE2C locus looping
drives castration-resistant prostate cancer growth. EMBO J.
30:2405–2419. 2011. View Article : Google Scholar : PubMed/NCBI
|
